Company / Cash & Equivalents
Barinthus Biotherapeutics plc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$70.5M
FY2025
5-year range
$70.5M / $214.1M
FY2021-FY2025
Trend
-36.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $214M in FY2021 to $70M in FY2025.
Based on SEC 10-K filings.
$70M in FY2025 with a 3-year CAGR of -28.7%.
Declined from $142M to $70M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -28.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Barinthus Biotherapeutics plc.'s cash & equivalents has declined for 4 consecutive years.
- 3-year CAGR of -28.7%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 36.3% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $70.5M | -36.3% |
| FY2024 | $110.7M | -22.1% |
| FY2023 | $142.1M | -26.9% |
| FY2022 | $194.4M | -9.2% |
| FY2021 | $214.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026